EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Multiplex PCR-pneumonia panel: usefulness and cost-considerations in a post-transplant cohort in a lower middle-income country

Muhammad Sharjeel, Memoona Irshad, Adnan Ali, Sanabil Khan, Ahmed Sheri

The Journal of Infection in Developing Countries · 2026-10-31 · 20 (10) · 1496-1502

DOI: 10.3855/jidc.21989 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Post-transplant pneumonia is a clinical challenge. This study evaluated the clinical utility and cost-considerations of the multiplex polymerase chain reaction pneumonia panel (mPCR-PP) in a low-resource clinical setting. Methodology: In this retrospective study, sputum or bronchoalveolar lavage (BAL) samples of 57 post-transplant adults with suspected lower respiratory tract infection were tested with mPCR-PP. The results were compared to standard cultures with the automated VITEK® system. The impact of mPCR testing on modulating antibiotic therapy was recorded. Cost implications of antibiotic changes were also estimated. Results: A total of 33 (57.9%) patients with liver, 23 (40.4%) patients with renal, and 1 (1.8%) patient with hematopoietic stem cell transplantation were included. The sensitivity and specificity of multiplex PCR were 75% and 53.3%, respectively. The positive predictive value was 72% and the negative predictive value was 57%. Multi-pathogen detection was noted in 17 (43.6%) cases with mPCR and 6 (15.4%) cases with cultures. A total of 75 bacterial pathogens were identified: Klebsiella pneumoniae (n = 19; 25.3%), Escherichia coli (n = 13; 17.3%), and Pseudomonas aeruginosa (n = 11; 14.6%). Resistance markers including CTX-M, NDM, and OXA-48-like were identified through mPCR. Antibiotic regimens of 15 (26.3%) patients were subsequently modified leading to 11.1% reduction in antibiotic prescriptions. Cost assessment for patients undergoing meropenem de-escalation (n = 8) revealed that up to $232 USD could have been saved per patient with early mPCR implementation. Conclusions: Multiplex PCR boosts pathogen detection and provides cost benefits which support its potential integration into management of post-transplant pneumonia.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →